A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need.
Submission deadline: 14 Dec 2026
buff.ly/Da8ENXI
#HRpositive #HER2negative #MedicalOncology

🚀 Zacks Small Cap Research - ATOS: Multiple Catalysts Converge in 2H26
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-atos-multiple-catalysts-converge-in-2h26/
#AtossaThe#AtossaTherapeuticsd#ATOSn#Endoxifene#ZEndoxifenn#BreastCancerv#ERpositivet#HER2NegativeN#EVANGELINE

Research suggests that 50% to 60% of cases labeled HER2-negative may actually be HER2-low, and 10% to 20% may be HER2-ultralow.

Learn why that matters and what it could mean for your treatment options here: https://bit.ly/3OTwUV2

#breastcancer #HER2negative #breastcancersurvivors

HR+/HER2‑ Breast Cancer Market Trends Reflect Rapid Adoption of Personalized Treatments

Source: roleplay.iland.top/blogs/11602/...

#HRPositive #HER2Negative #BreastCancerMarket #OncologyMarket #CancerTherapeutics

In a phase 3 trial, #culmerciclib plus #fulvestrant improved PFS and response rates versus fulvestrant alone in pretreated #HRPositive, #HER2Negative advanced #BreastCancer, supporting dual CDK2/4/6 targeting to overcome resistance.

#OpenAccess in #STTT: doi.org/10.1038/s413...

Lynparza just showed long-term survival benefits for breast cancer patients after 6 years of follow-up. A huge step forward in treatment!
#breastcancer #CancerResearch #CancerTreatment #Lynparza #BRCA #HER2Negative #HopeForCancer #MedicalInnovation #PharmaNews #CancerAwareness #BreastCancer